Growth Hormone Peptides ·
This study investigates the effects of paracellular permeation enhancers on the intestinal absorption of Hexarelin. Hexarelin, a peptide with a molecular weight of 887 Da, has been shown to have limited intestinal permeability. Understanding the factors that influence its absorption is crucial for optimizing its therapeutic applications.
What this study examined
The research focused on the intestinal permeability of two peptide drugs: enalaprilat and Hexarelin, using a rat single-pass intestinal perfusion model. The study involved the administration of paracellular permeation enhancers, specifically chitosan and ethylenediaminetetraacetate (EDTA), in varying concentrations. Additionally, the effects of low luminal tonicity and lidocaine on drug absorption were evaluated through concomitant blood sampling to measure the permeability changes of both peptides.
Why it matters for Hexarelin research
This study provides insights into the mechanisms that govern the intestinal absorption of Hexarelin, particularly in relation to its molecular weight and permeability characteristics. The findings suggest that while Hexarelin has limited absorption through transcellular pathways, the use of paracellular permeability enhancers could potentially improve its intestinal absorption. This is particularly relevant for researchers looking to enhance the bioavailability of peptide drugs like Hexarelin, which may have therapeutic applications in various clinical settings.
Key findings
- Paracellular permeation enhancers significantly increased the intestinal permeability of both Hexarelin and enalaprilat.
- Chitosan and EDTA were effective in enhancing mucosal permeability in the study.
- Low luminal tonicity did not affect the absorption of Hexarelin or enalaprilat.
- The study utilized a rat model to evaluate the effects of these enhancers on drug absorption.
- The mucosal blood-to-lumen flux of 51 chromium-labeled EDTA increased with the use of permeation enhancers.
- Hexarelin's absorption is primarily limited by its size and the mechanisms of transport across intestinal barriers.
How Hexarelin works (background)
Hexarelin is a synthetic peptide that belongs to the growth hormone-releasing peptide (GHRP) class. It acts by stimulating the pituitary gland to release growth hormone, which plays a vital role in various physiological processes, including metabolism and tissue growth. The mechanism of action involves binding to specific receptors in the hypothalamus and pituitary, leading to an increase in endogenous growth hormone levels. However, the absorption of Hexarelin through the gastrointestinal tract is hindered by its relatively large molecular size, which limits its ability to permeate cellular barriers effectively.
Practical takeaways for researchers
For researchers working with Hexarelin, understanding the role of paracellular permeability enhancers can be crucial for improving its bioavailability. The findings of this study suggest that employing such enhancers in formulations may lead to better absorption profiles for Hexarelin and similar peptides. This could have implications for the development of oral delivery systems for peptide therapeutics, potentially enhancing their clinical utility.
FAQ
What is Hexarelin used for?
Hexarelin is primarily investigated for its potential to stimulate growth hormone release, which may have applications in growth disorders, muscle wasting, and other metabolic conditions.
How does Hexarelin compare to other peptides?
Hexarelin is part of the GHRP family and is characterized by its ability to promote growth hormone secretion, similar to other peptides but with unique pharmacokinetic properties.
Can Hexarelin be administered orally?
Oral administration of Hexarelin poses challenges due to its low intestinal permeability; however, research into permeation enhancers may improve its bioavailability through this route.
Source: PubMed · Acta Pharm Sin B · published 2021-06-01.